Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
- PMID: 21455215
- PMCID: PMC4641450
- DOI: 10.1038/leu.2011.58
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
Figures

Similar articles
-
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.Leukemia. 2011 May;25(5):877-9. doi: 10.1038/leu.2011.10. Epub 2011 Feb 22. Leukemia. 2011. PMID: 21339759 No abstract available.
-
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.Leukemia. 2011 Jul;25(7):1219-20. doi: 10.1038/leu.2011.82. Epub 2011 Apr 26. Leukemia. 2011. PMID: 21519343 Free PMC article. No abstract available.
-
EZH2 mutational status predicts poor survival in myelofibrosis.Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14. Blood. 2011. PMID: 21921040
-
New mutations and pathogenesis of myeloproliferative neoplasms.Blood. 2011 Aug 18;118(7):1723-35. doi: 10.1182/blood-2011-02-292102. Epub 2011 Jun 7. Blood. 2011. PMID: 21653328 Review.
-
Genetics of the myeloproliferative neoplasms.Curr Opin Hematol. 2011 Mar;18(2):117-23. doi: 10.1097/MOH.0b013e328343998e. Curr Opin Hematol. 2011. PMID: 21307773 Review.
Cited by
-
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.J Hematol Oncol. 2012 Mar 21;5:12. doi: 10.1186/1756-8722-5-12. J Hematol Oncol. 2012. PMID: 22436456 Free PMC article. Review.
-
ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion.Haematologica. 2018 Dec;103(12):1980-1990. doi: 10.3324/haematol.2018.189928. Epub 2018 Aug 9. Haematologica. 2018. PMID: 30093396 Free PMC article.
-
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.Curr Oncol Rep. 2019 Nov 14;21(11):101. doi: 10.1007/s11912-019-0855-6. Curr Oncol Rep. 2019. PMID: 31728739 Review.
-
Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm.Cells. 2022 Dec 27;12(1):105. doi: 10.3390/cells12010105. Cells. 2022. PMID: 36611899 Free PMC article. Review.
-
The role of ASXL1 in hematopoiesis and myeloid malignancies.Cell Mol Life Sci. 2019 Jul;76(13):2511-2523. doi: 10.1007/s00018-019-03084-7. Epub 2019 Mar 30. Cell Mol Life Sci. 2019. PMID: 30927018 Free PMC article. Review.
References
-
- Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365–375. - PubMed
-
- Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42:722–726. - PubMed
-
- Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183–2186. - PubMed
-
- Boultwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia. 2010;24:1139–1145. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials